Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.

178 withdrew before random assignment and 1544 were disqualified.

441 (63%) of 698 participants were female and 257 (37%) were male.

484 (69%) of 698 participants were White and 172 (25%) were Asian.

Similarly, the proportions of participants achieving this endpoint in the two groups that combined lower doses of zalfermin with semaglutide 2·4 mg and in the exploratory group combining cagrilintide 2·4 mg with semaglutide 2·4 mg were not substantially different than with placebo.